1. Designing multi-epitope based peptide vaccine candidates against SARS-CoV-2 using immunoinformatics approach

Ysrafil Ysrafil* , Zulfiayu Sapiun , Indwiani Astuti , Mohammad Anas Anasiru, Nangsih Sulastri Slamet , Hartati Hartati , Fadli Husain, Sukmawati Ahmad Damiti

BioImpacts. 2022;12(4): 359-370. doi: 10.34172/bi.2022.23769

PMCID: PMC9376164 PMID: 35975206 Scopus ID: 85138027836

Article

PDF

Suppl 1

Full Text

XML

Cited By:

The two designed and constructed multiepitope vaccine have good characteristics and may have the potential to activate humoral and cellular immune responses against SARS-CoV-2. Further research is worth considering to confirm the findings of this study.

Original Article

2. A novel therapeutic multiepitope vaccine based on oncoprotein E6 and E7 of HPV 16 and 18: An in silico approach

Sari Eka Pratiwi* , Ysrafil Ysrafil , Mardhia Mardhia , Mahyarudin Mahyarudin , Muhammad Inam Ilmiawan, Heru Fajar Trianto, Delima Fajar Liana, Yuri Amia

Bioimpacts. 2024;14(5): 27846. doi: 10.34172/bi.2024.27846

PMCID: PMC11406424 PMID: 39296802 Scopus ID: 85209247503

Article

PDF

Suppl 1

XML

Cited By:

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate: 24%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded, Google Scholar; SJR ; Essential Science Indicators; Publons; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO; Ulrich
Member of COPE
Follower of ICMJE
Permission: Creative Commons